The role of exogenous estrogen in the initiation and maintenance of human SLE remains very controversial. Although cohort studies suggest an increase in the incidence of SLE with both oral contraceptives and hormone replacement therapy, recent retrospective studies suggest that the risk of flare is not increased with hormone replacement therapy. However, exogenous estrogen does increase hypercoagulability, an issue in SLE patients with antiphospholipid antibodies. The prospective SELENA study will ultimately address whether exogenous estrogen increases severe flares in SLE.
Roubinian J , Talal N , Siiteri PK , Sadakian JA . Sex hormone modulation of autoimmunity in NZB/NZW mice . Arthritis Rheum1979; 22: 1162-1169 .
2.
Steinberg AD , Melez KA , Raveche ES et al. Approach to the study of the role of sex hormones in autoimmunity . Arthritis Rheum1979; 22: 1170-1176 .
3.
Verthelyi D , Petri M , Yialamas M , Klinman D . Disassociation of sex hormone levels and cytokine production in SLE patients. Lupus2001 (in press).
4.
Tarzy BJ , Garcia CR , Wallach EE et al. Rheumatic disease, abnormal serology and oral contraceptives . Lancet1972; ii: 501-503 .
5.
Sanchez-Guerrero J , Karlson EW , Liang MH et al. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus . Arthritis Rheum1997; 40: 804-808 .
Garovich M , Agudelo C , Pisko E . Oral contraceptives and systemic lupus erythematosus . Arthritis Rheum1980; 23: 1396-1398 .
8.
Todd GR , McAteer EJ , Jack CM et al. Pulmonary hypertension, systemic lupus erythematosus, and the contraceptive pill . Ann Rheum Dis1985; 44: 266-267 .
9.
Julkunen H , Kaaja R , Jouhikainen T et al. Malignant hypertension and antiphospholipid antibodies as presenting features of SLE in a young woman using oral contraceptives . Br J Rheumatol1991; 30: 471-472 .
10.
Julkunen HA . Oral contraceptives in systemic lupus erythematosus: side-effects and influence on the activity of SLE . Scand J Rheumatol1991; 20: 427-433 .
11.
Pimstone B . Systemic lupus erythematosus exacerbated by oral contraceptives . S Afr J Obstet Gynaecol1966; 62-63 .
12.
Hadida M , Sayag J . Lupus erythemateus subanu apparu apres une cure du Norfutin chez une malade atteinte de lupus erythematreux chronique . Soc Franc Derm Syph Bull1968; 74: 616-621 .
13.
Chapel TA , Burns RE . Oral contraceptives and exacerbation of lupus erythematosus . Am J Obstet Gynecol1971; 110: 366-369 .
14.
Laugier P , Orusco P , Chatelanat F et al. Lupus érythémateux disseminé induit par estrogénes . Bull Soc Fr Dermatol Syphiligr1971; 78: 623-628 .
15.
Miller MH . Pulmonary hypertension, systemic lupus erythematosus, and the contraceptive pill: another report . Ann Rheum Dis1987; 46: 159-161 .
16.
Jungers P , Dougados M , Pelissier C et al. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus . Arthritis Rheum1982; 25: 618-623 .
17.
Buyon JP , Kalunian KC , Skovron ML et al. Can women with systemic lupus erythematosus safely use exogenous estrogens?J Clin Rheumatol1995; 1: 205-212 .
18.
Lautenbach GL , Petri M . Women's health . Rheum Dis Clinics N Am2000; 25: 539-566 .
19.
Petri M , Howard D , Repke J . Frequency of lupus flare in pregnancy: the Hopkins Lupus Pregnancy Center experience . Arthritis Rheum1991; 34: 1538-1545 .
20.
Ruiz-Irastorza G , Lima F , Alves J et al. Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies . Br J Rheumatol1996; 35: 133-138 .
21.
Yell JA , Burge SM . The effect of hormonal changes on cutaneous disease in lupus erythematosus . Br J Dermatol1993; 129: 18-22 .
22.
Steinberg AD , Steinberg BJ . Lupus disease activity associated with menstrual cycle [letter] . J Rheumatol1985; 12: 816-817 .
23.
Pando JA , Gourley MF , Wilder RL , Crofford LJ . Hormonal supple-mentation as treatment for cyclical rashes in patients with systemic lupus erythematosus . J Rheumatol1995; 22: 2159-2162 .
24.
Lindsay R . The effect of sex steroids on the skeleton in premenopausal women . Am J Obstet Gynecol1992; 166: 1993-1996 .
25.
Petri M . Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update . Arthritis Care Res1995; 8: 137-145 .
26.
Recommendations for the prevention and treatment of glucocorticoidinduced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines . Arthritis Rheum1996; 39: 1791-1801 .
27.
Boumpas DT , Austin III HA , Vaughan EM et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy . Ann Intern Med1993; 119: 366-369 .
28.
Langevitz P , Klein L , Pras M , Many A . The effect of cycolphosphamide pulses on fertility in patients with lupus nephritis . Am J Reprod Immunol1992; 28: 157-158 .
29.
Mok CC , Lau CS , Wong RWS . Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy . Arthritis Rheum1998; 41: 831-837 .
30.
Wang CL , Wang F , Bosco JJ . Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus . Lupus1995; 4: 11-14 .
31.
Chapman RM , Sutcliffe SB . Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's dis-ease . Blood1981; 58: 849-851 .
32.
Blumenfeld Z , Avivi I , Linn S et al. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotropin-releasing hormone agonist in parallel to chemotherapy . Hum Reprod1996; 11: 1620-1626 .
33.
Blumenfeld Z , Shapiro D , Shteinberg M et al. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy . Lupus2000; 9: 401-405 .
34.
World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study . Lancet1995; 346: 1575-1582 .
35.
Jick H , Jick SS , Gurewich V et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components . Lancet1995; 346: 1589-1593 .
36.
Spitzer WO , Lewis MA , Heinemann LAJ et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study . Br Med J1996; 312: 83-88 .
37.
Lewis MA , Spitzer WO , Heinemann LAJ et al. Third generation oral contraceptives a risk of myocardial infarction: an international case-control study . Br Med J1996; 312: 88-90 .
38.
Petitti D , Sidney S , Bernstein A et al. Stroke in users of low-dose oral contraceptives . New Engl J Med1996; 335: 8-15 .
39.
Asherson RA , Harris EN , Hughes GRV . Complications of oral contraceptives and antiphospholipid antibodies [letter] . Arthritis Rheum1988; 31: 575-576 .
40.
Bloemenkamp KWM , Rosendaal FR , Helmerhorst FM et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen . Lancet1995; 346: 1593-1596 .
41.
Sanchez-Guerrero J , Liang MH , Karlson EW et al. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus . Ann Intern Med1995; 122: 430-433 .
42.
Barrett C , Neylon N , Snaith ML . Oestrogen-induced systemic lupus erythematosus . Br J Rheumatol1986; 25: 300-301 .
43.
Arden NK , Lloyd ME , Spector TD , Hughes GRV . Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE) . Lupus1994; 3: 11-13 .
Simms RW , Anderson JJ , Zerbini A , Felson DT . Treatment of glucocorticoid-induced osteoporosis: a meta-analysis [abstract] . Arthritis Rheum1993; 36(Suppl 9): S50-S50 .
46.
Nachtigall LE , Nachtigall RH , Nachtigall RD , Beckman EM . Estrogen replacement therapy I: a ten-year prospective study on the relationship to osteoporosis . Obstet Gynecol1979; 53: 277-281 .
47.
Belchetz PE . Hormonal treatment of postmenopausal women . New Engl J Med1994; 330: 1062-1070 .
48.
Wolf PH , Madans JH , Finucane FF et al. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort . Am J Obstet Gynecol1991; 164: 489-494 .
49.
Hulley S , Grady D , Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group . JAMA1998; 280: 605-613 .
50.
Fitzpatrick LA , Litin SC , Bell MR . The Women's Health Initiative: a heart-to-HRT conversation [editorial] . Mayo Clinic Proc2000; 75: 559-561 .
51.
Herrington DM , Reboussin DM , Brosnihan KB et al. Effects of estrogen replacement on the progression of coronary-artery athero-sclerosis . New Engl J Med2000; 343: 522-529 .
52.
Yaffe K , Grady D , Pressman A , Cummings SR . Serum estrogen levels, cognitive performance, and risk of cognitive decline in older community women . J Am Geriatr Soc1998; 46: 816-821 .
53.
Tang M , Jacobs D , Stern Y et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease . Lancet1996; 348: 4229-4432 .
54.
Kampen DL , Sherwin BB . Estrogen use and verbal memory in healthy postmenopausal women . Obstet Gynecol1994; 83: 979-983 .
55.
Asthana S , Craft S , Baker L et al. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study . Psychoendocrinology1999; 24: 657-677 .
56.
Polo-Kantola P , Portin R , Polo O et al. The effect of short-term estrogen replacement therapy on cognition: a randomized double-blind, cross-over trial in postmenopausal women . Obstet Gynecol1998; 91: 459-466 .
57.
Mulnard R , Cotman C , Kawas C et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease . JAMA2000; 283: 1007-1015 .
58.
Yaffe K , Lui L-Y , Grady D et al. Cognitive decline in women in relation to non-protein-bound oestradiol concentrations . Lancet2000; 356: 708-712 .
59.
Tierney MC . Oestradiol concentrations in prediction of cognitive decline in women . Lancet2000; 356: 694-695 .
60.
Pike MC , Peters RK , Cozen W et al. Estrogen-progestin replacement therapy and endometrial cancer . J Natl Cancer Inst1997; 89: 1110-1116 .
61.
Ross RK , Paganini-Hill A , Wan PC , Pike MC . Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin . J Natl Cancer Inst2000; 92: 328-332 .
62.
Schairer C , Lubin J , Troisi R et al. Menopausal estrogen and estrogenprogestin replacement therapy and breast cancer risk . JAMA2000; 283: 485-491 .
